Related Experiment Video

Updated: Feb 24, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular

Xiaotian Kong1,2, Huiyong Sun2, Peichen Pan2

  • 1Institute of Functional Nano and Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China.

Scientific Reports
|August 24, 2017
PubMed

Insights

The L884P mutation in Janus kinase 2 (JAK2) causes resistance to Type-II inhibitors like BBT594 and CHZ868 by altering binding pockets. This molecular insight aids in developing new treatments for myeloproliferative neoplasms (MPNs).

Area of Science:

  • Biochemistry
  • Pharmacology
  • Computational Biology

Background:

  • Janus kinase 2 (JAK2) is a key target for treating myeloproliferative neoplasms (MPNs).
  • Type-II JAK2 inhibitors BBT594 and CHZ868 show efficacy but are affected by the JAK2 L884P mutation.
  • Understanding resistance mechanisms is crucial for effective MPN therapies.

Purpose of the Study:

  • To investigate how the JAK2 L884P mutation influences the binding of BBT594 and CHZ868.
  • To elucidate the molecular mechanisms underlying drug resistance induced by the L884P mutation.

Main Methods:

  • Conventional molecular dynamics (MD) simulations.
  • Umbrella sampling (US) simulations.
  • MM/GBSA free energy calculations.

Main Results:

  • The L884P mutation increases allosteric pocket flexibility and alters conformations, weakening inhibitor binding.
  • Conformational entropy changes (-TΔS) are amplified by the mutation, contributing to resistance.
  • Drug tail characteristics (electronegativity, size) in the WT JAK2 allosteric pocket may offer anti-resistance potential.

Conclusions:

  • Both conformational entropy and enthalpy changes contribute to L884P-induced resistance in JAK2 inhibitors.
  • Findings provide insights into designing next-generation JAK2 inhibitors with improved resistance profiles for MPNs.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.9K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.8K